Deutsche Bank Updates

Deutsche Bank reiterates its Hold rating on Quest Diagnostics (NYSE: DGX). At the same time, Deutsche Bank left its price target unchanged at $63.

In a research report published today, Deutsche Bank states, "DGX's relative under-performance to its close peer, LH, has grown wider in recent years and, in our view, is becoming a “sore” point w/ investors. We assume DGX's board would take the co's absolute and relative performance into close consideration in the context of the CEO's impending employment contract renewal." On Wednesday, Quest Diagnostics closed the day at $58.18.

Crown Castle (NYSE: CCI) had its rating and price target maintained. At the moment, Deutsche Bank has a Buy rating and a price target of $57 on the company's stock.

In the report, Deutsche Bank states, "Crown Castle (CCI) has underperformed the S&P 500 by 12.5%, REITs by 16.3% and American Tower (AMT) by 13.0%. As a result of this underperformance, the stock is approaching historical floor valuations and trading at a steep discount to key comps despite a number of potential positive catalysts in 2H11." On Wednesday, Crown Castle's shares closed at $41.